Explain this page
Arphra AIPlain-English read on Merck & Co., Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$127.05
+6.72% vs spot
Recommendation
Hold
19 of 20 methods
Method spread
6bull13bear
±5% threshold
Analyst PT consensus: $130.69 (+9.78%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.42% | -1.49% | +4.94% | +2.98% | +18.69% | +13.10% | +45.70% | +8.24% | +57.79% | +122.52% | +30011.04% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$23.26M
10 txns
Net flow
−$23.26M
Aftermarket
LiveLast trade
$119.33
Bid
$119.11
200 sh
Ask
$119.36
200 sh
Spread
$0.250
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $16.29B | -$4.24B | $-1.72 |
| Q4 Dec 2025 | $16.32B | $2.96B | $1.19 |
| Q3 Sep 2025 | $17.18B | $5.79B | $2.32 |
| Q2 Jun 2025 | $15.8B | $4.43B | $1.76 |
| Q1 Mar 2025 | $15.62B | $5.08B | $2.01 |
| Q4 Dec 2024 | $15.62B | $3.74B | $1.48 |
Analyst view
DB · price_targets + analyst_gradesConsensus target
$130.69
+9.78% upside
Low
$100.00
Median
$135.00
High
$150.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?zacks.com·Jun 12, 2026
- Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowingzacks.com·Jun 11, 2026
- Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Knowzacks.com·Jun 11, 2026
- Merck Animal Health to Acquire TARGANbusinesswire.com·Jun 11, 2026
- Merck Animal Health to Acquire TARGANbusinesswire.com·Jun 11, 2026
- Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Casezacks.com·Jun 10, 2026
- Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 09, 2026
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Studybusinesswire.com·Jun 08, 2026
Recent analyst activity
DB- Jun 02, 2026GradeNeutral → NeutralMerck (MRK) Reiterated at Neutral by Cantor FitzgeraldCantor Fitzgerald
- Jun 02, 2026GradeBuy → BuyGuggenheim Reiterates Buy Rating on Merck (MRK)Guggenheim
- Jun 02, 2026PT$140.00Guggenheim Reiterates Buy Rating on Merck (MRK)Guggenheim
Peers
Total assets
$136.87B
Total debt
$50.53B
Cash & equiv
$14.57B
Operating CF
$16.47B
Free cash flow
$12.36B
Buybacks
-$5.08B
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Guindo Chirfi officer: Chief Marketing Officer | Sell | 10,000 | $1.21M | Feb 12, 2026 |
Li Dean Y officer: Executive VP & President, MRL | Sell | 10,235 | $1.2M | Feb 10, 2026 |
Zachary Jennifer officer: EVP, General Counsel | Sell | 38,835 | $4.63M | Feb 09, 2026 |
Guindo Chirfi officer: Chief Marketing Officer | Sell | 10,000 | $1.18M | Feb 09, 2026 |
Oosthuizen Johannes Jacobus officer: President, U.S. Market | Sell | 15,000 | $1.83M | Feb 06, 2026 |
DeLuca Richard R. officer: EVP&Pres, Merck Animal Heallth | Sell | 37,685 | $4.56M | Feb 06, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $64.93B | $23.49B | $18.25B | $7.28 | +28.12% |
| FY 2024 | $64.17B | $20.22B | $17.12B | $6.74 | +26.68% |
| FY 2023 | $60.12B | $2.95B | $365M | $0.14 | +0.61% |
| FY 2022 | $59.28B | $18.28B | $14.52B | $5.71 | +24.49% |
| FY 2021 | $48.7B | $13.2B | $13.05B | $5.14 | +26.79% |